{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:34:45Z","timestamp":1791117285618,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Doctor Hadwen Trust"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.neuropharm.2015.06.013","type":"journal-article","created":{"date-parts":[[2015,6,24]],"date-time":"2015-06-24T21:32:22Z","timestamp":1435181542000},"page":"566-575","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["An in\u00a0vitro model for synaptic loss in neurodegenerative diseases suggests a neuroprotective role for valproic acid via inhibition of cPLA2 dependent signalling"],"prefix":"10.1016","volume":"101","author":[{"given":"Robin S.B.","family":"Williams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Bate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2015.06.013_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1750-1326-5-13","article-title":"Phospholipase A2 inhibitors protect against prion and A\u03b2 mediated synapse degeneration","volume":"5","author":"Bate","year":"2010","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib2","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.neuropharm.2007.05.003","article-title":"Squalestatin protects neurons and reduces the activation of cytoplasmic phospholipase A2 by A\u03b21\u201342","volume":"53","author":"Bate","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2015.06.013_bib3","doi-asserted-by":"crossref","first-page":"37955","DOI":"10.1074\/jbc.M111.248724","article-title":"Amyloid-\u03b2-induced synapse damage is mediated via cross-linkage of the cellular prion protein","volume":"286","author":"Bate","year":"2011","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib4","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s00213-005-0272-4","article-title":"Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder","volume":"184","author":"Bazinet","year":"2006","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib5","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nn.3028","article-title":"The toxic A[beta] oligomer and Alzheimer's disease: an emperor in need of clothes","volume":"15","author":"Benilova","year":"2012","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib6","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1046\/j.1471-4159.2003.01701.x","article-title":"Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain","volume":"85","author":"Bosetti","year":"2003","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib7","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1111\/j.1528-1167.2009.02412.x","article-title":"Inhibition of long-term potentiation by valproic acid through modulation of cyclic AMP","volume":"51","author":"Chang","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2015.06.013_bib8","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1242\/dmm.008029","article-title":"The antiepileptic drug valproic acid and other medium-chain fatty acids acutely reduce phosphoinositide levels independently of inositol in Dictyostelium","volume":"5","author":"Chang","year":"2012","journal-title":"Dis. Model Mech."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib9","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1152\/jn.00696.2004","article-title":"Endogenous PGE2 regulates membrane excitability and synaptic transmission in hippocampal CA1 pyramidal neurons","volume":"93","author":"Chen","year":"2005","journal-title":"J.\u00a0Neurphysiol."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib10","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1242\/dmm.008391","article-title":"Conserved valproic-acid-induced lipid droplet formation in Dictyostelium and human hepatocytes identifies structurally active compounds","volume":"5","author":"Elphick","year":"2012","journal-title":"Dis. Model Mech."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib11","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.bcp.2005.02.012","article-title":"Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives","volume":"69","author":"Eyal","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/14734220260418448","article-title":"Synaptic pathology and cell death in the cerebellum in Creutzfeldt-Jakob disease","volume":"1","author":"Ferrer","year":"2002","journal-title":"Cerebellum"},{"key":"10.1016\/j.neuropharm.2015.06.013_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.neurobiolaging.2005.10.018","article-title":"Increased cholesterol in A[beta]-positive nerve terminals from Alzheimer's disease cortex","volume":"28","author":"Gylys","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2015.06.013_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/156720506775697098","article-title":"Has the amyloid cascade hypothesis for Alzheimer's disease been proved?","volume":"3","author":"Hardy","year":"2006","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib15","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1056\/NEJMoa0907328","article-title":"Valproic acid monotherapy in pregnancy and major congenital malformations","volume":"362","author":"Jentink","year":"2010","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib16","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/29079","article-title":"Kinetics and regulation of fast endocytosis at hippocampal synapses","volume":"394","author":"Klingauf","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2015.06.013_bib17","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1523\/JNEUROSCI.4564-06.2007","article-title":"Presynaptic \u03b1-synuclein aggregates, not Lewy bodies, cause neurodegeneration in Dementia with Lewy bodies","volume":"27","author":"Kramer","year":"2007","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib18","doi-asserted-by":"crossref","first-page":"10191","DOI":"10.1523\/JNEUROSCI.3432-04.2004","article-title":"Synaptic targeting by Alzheimer's-related Amyloid \u03b2 Oligomers","volume":"24","author":"Lacor","year":"2004","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib19","doi-asserted-by":"crossref","first-page":"13266","DOI":"10.1073\/pnas.95.22.13266","article-title":"Amyloid beta peptide alters intracellular vesicle trafficking and cholesterol homeostasis","volume":"95","author":"Liu","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2174\/1567205011310030005","article-title":"Valproic acid attenuates neuronal loss in the brain of APP\/PS1 double transgenic Alzheimer's disease mice model","volume":"10","author":"Long","year":"2013","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib21","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nature04399","article-title":"Role of cholesterol and lipid organization in disease","volume":"438","author":"Maxfield","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2015.06.013_bib22","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.bbalip.2013.01.008","article-title":"Propylisopropylacetic acid (PIA), a constitutional isomer of valproic acid, uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: a potential drug for bipolar disorder","volume":"1831","author":"Modi","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.neuropharm.2015.06.013_bib23","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1212\/WNL.53.7.1495","article-title":"Elevated CSF prostaglandin E2 levels in patients with probable AD","volume":"53","author":"Montine","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2015.06.013_bib24","doi-asserted-by":"crossref","first-page":"18239","DOI":"10.1016\/S0021-9258(17)32440-7","article-title":"Delineation of two functionally distinct domains of cytosolic phospholipase A2, a regulatory Ca(2+)-dependent lipid-binding domain and a Ca(2+)-independent catalytic domain","volume":"269","author":"Nalefski","year":"1994","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib25","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib26","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1042\/bj20031672","article-title":"Lipid rafts: heterogeneity on the high seas","volume":"378","author":"Pike","year":"2004","journal-title":"Biochem. J."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib27","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1084\/jem.20081588","article-title":"Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models","volume":"205","author":"Qing","year":"2008","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib28","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/archpsyc.59.7.592","article-title":"Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder?","volume":"59","author":"Rapoport","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.neuropharm.2015.06.013_bib29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3233\/JAD-2005-7203","article-title":"Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction","volume":"7","author":"Reddy","year":"2005","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib30","doi-asserted-by":"crossref","first-page":"48146","DOI":"10.1074\/jbc.M307295200","article-title":"Structural properties of Gerstmann-Straussler-Scheinker disease amyloid protein","volume":"278","author":"Salmona","year":"2003","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib31","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/nn.2213","article-title":"Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease","volume":"11","author":"Sanchez-Mejia","year":"2008","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib32","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.biopsych.2009.11.008","article-title":"Hippocampal synaptic plasticity, memory, and epilepsy: effects of long-term valproic acid treatment","volume":"67","author":"Sgobio","year":"2010","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2015.06.013_bib33","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm1782","article-title":"Amyloid-\u03b2 protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory","volume":"14","author":"Shankar","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib34","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1471-4159.2008.05347.x","article-title":"Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons","volume":"106","author":"Shelat","year":"2008","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib35","doi-asserted-by":"crossref","first-page":"6899","DOI":"10.1021\/bi035627j","article-title":"Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing","volume":"43","author":"Su","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2015.06.013_bib36","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1042\/BST0371126","article-title":"Structure-function studies for the panacea, valproic acid","volume":"37","author":"Terbach","year":"2009","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib37","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/ana.410300410","article-title":"Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment","volume":"30","author":"Terry","year":"1991","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib38","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.brainres.2005.12.045","article-title":"Synaptosomal glutamate release and uptake in mice lacking the cellular prion protein","volume":"1075","author":"Thais","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib39","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.neuron.2004.09.010","article-title":"Deciphering the molecular basis of memory failure in Alzheimer's disease","volume":"44","author":"Walsh","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2015.06.013_bib40","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1096\/fj.07-9766com","article-title":"Membrane-bound \u03b2-amyloid oligomers are recruited into lipid rafts by a fyn-dependent mechanism","volume":"22","author":"Williamson","year":"2008","journal-title":"FASEB J."},{"key":"10.1016\/j.neuropharm.2015.06.013_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2014.01.051","article-title":"Neuroprotective and anti-apoptotic effects of valproic acid on adult rat cerebral cortex through ERK and Akt signaling pathway at acute phase of traumatic brain injury","volume":"1555","author":"Zhang","year":"2014","journal-title":"Brain Res."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390815002713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390815002713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T17:03:35Z","timestamp":1751043815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390815002713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":41,"alternative-id":["S0028390815002713"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2015.06.013","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An in\u00a0vitro model for synaptic loss in neurodegenerative diseases suggests a neuroprotective role for valproic acid via inhibition of cPLA2 dependent signalling","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2015.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}